AU2018250552B2 - Chk1 (SRA737)/PARPi combination methods of inhibiting tumor growth - Google Patents

Chk1 (SRA737)/PARPi combination methods of inhibiting tumor growth Download PDF

Info

Publication number
AU2018250552B2
AU2018250552B2 AU2018250552A AU2018250552A AU2018250552B2 AU 2018250552 B2 AU2018250552 B2 AU 2018250552B2 AU 2018250552 A AU2018250552 A AU 2018250552A AU 2018250552 A AU2018250552 A AU 2018250552A AU 2018250552 B2 AU2018250552 B2 AU 2018250552B2
Authority
AU
Australia
Prior art keywords
cancer
parpi
subject
sra737
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018250552A
Other languages
English (en)
Other versions
AU2018250552A1 (en
Inventor
Kenna Lynn Anderes
Ryan James HANSEN
Christian Andrew HASSIG
Bryan William STROUSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crt Pioneer Fund Lp
Original Assignee
Crt Pioneer Fund Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crt Pioneer Fund Lp filed Critical Crt Pioneer Fund Lp
Publication of AU2018250552A1 publication Critical patent/AU2018250552A1/en
Application granted granted Critical
Publication of AU2018250552B2 publication Critical patent/AU2018250552B2/en
Priority to AU2022259818A priority Critical patent/AU2022259818A1/en
Assigned to CRT PIONEER FUND LP reassignment CRT PIONEER FUND LP Request for Assignment Assignors: SIERRA ONCOLOGY, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018250552A 2017-04-10 2018-04-10 Chk1 (SRA737)/PARPi combination methods of inhibiting tumor growth Active AU2018250552B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022259818A AU2022259818A1 (en) 2017-04-10 2022-10-27 Chk1 (SRA737)/PARPi combination methods of inhibiting tumor growth

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762483888P 2017-04-10 2017-04-10
US62/483,888 2017-04-10
US201762552364P 2017-08-30 2017-08-30
US62/552,364 2017-08-30
US201862614268P 2018-01-05 2018-01-05
US62/614,268 2018-01-05
US201862635394P 2018-02-26 2018-02-26
US62/635,394 2018-02-26
US201862650185P 2018-03-29 2018-03-29
US62/650,185 2018-03-29
PCT/US2018/026917 WO2018191277A1 (en) 2017-04-10 2018-04-10 Chk1 (sra737)/parpi combination methods of inhibiting tumor growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022259818A Division AU2022259818A1 (en) 2017-04-10 2022-10-27 Chk1 (SRA737)/PARPi combination methods of inhibiting tumor growth

Publications (2)

Publication Number Publication Date
AU2018250552A1 AU2018250552A1 (en) 2019-11-14
AU2018250552B2 true AU2018250552B2 (en) 2022-08-04

Family

ID=63793688

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018250552A Active AU2018250552B2 (en) 2017-04-10 2018-04-10 Chk1 (SRA737)/PARPi combination methods of inhibiting tumor growth
AU2022259818A Abandoned AU2022259818A1 (en) 2017-04-10 2022-10-27 Chk1 (SRA737)/PARPi combination methods of inhibiting tumor growth

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022259818A Abandoned AU2022259818A1 (en) 2017-04-10 2022-10-27 Chk1 (SRA737)/PARPi combination methods of inhibiting tumor growth

Country Status (9)

Country Link
US (1) US11596637B2 (enExample)
EP (1) EP3609884A4 (enExample)
JP (1) JP7273791B2 (enExample)
KR (1) KR102645511B1 (enExample)
CN (2) CN110582490A (enExample)
AU (2) AU2018250552B2 (enExample)
CA (1) CA3059576A1 (enExample)
MX (1) MX2019012176A (enExample)
WO (1) WO2018191277A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222970A1 (en) * 2017-06-01 2018-12-06 Sierra Oncology, Inc. Biomarkers and patient selection strategies
US20200397796A1 (en) * 2018-02-26 2020-12-24 Sierra Oncology, Inc. Methods of treatment of cancer comprising chk1 inhibitors
US20220184091A1 (en) * 2019-03-28 2022-06-16 Sierra Oncology, Inc. Methods of Treating Cancer with Chk1 Inhibitors
AU2020274164A1 (en) * 2019-05-14 2021-11-25 Sierra Oncology, Inc. Methods of treating cancer using Chk1 inhibitors
KR102285996B1 (ko) * 2019-08-08 2021-08-05 차의과학대학교 산학협력단 혈관신생을 억제하는 데 사용하기 위한 조성물 및 그 용도
EP4087563A4 (en) * 2020-01-07 2024-03-27 Shanghai Huayu Biotechnology Co., Ltd. CANCER COMBINATION THERAPY USING A CHK INHIBITOR
KR20230098134A (ko) * 2020-08-12 2023-07-03 바운드리스 바이오, 인크. 복제 스트레스 경로 제제 조성물 및 암의 치료 방법
TW202245777A (zh) * 2021-02-16 2022-12-01 美商律幫治療股份有限公司 Parp7抑制劑之給藥方案

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171470A1 (en) * 2012-05-15 2013-11-21 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US20050250836A1 (en) * 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
RU2009147819A (ru) * 2007-05-25 2011-06-27 Астразенека Аб (Se) Комбинация ингибиторов снк и parp для лечения злокачественных новообразований
WO2009099601A2 (en) 2008-02-04 2009-08-13 Dana-Farber Cancer Institute, Inc. Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
EP2640386B1 (en) 2010-11-16 2017-01-18 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
GB201316526D0 (en) * 2013-09-17 2013-10-30 King S College London Biomarkers
WO2015077602A1 (en) 2013-11-22 2015-05-28 Fred Hutchinson Cancer Research Center Methods for identifying therapeutic targets and treating and monitoring cancers
WO2018191299A1 (en) 2017-04-10 2018-10-18 Sierra Oncology, Inc. Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
WO2018222970A1 (en) 2017-06-01 2018-12-06 Sierra Oncology, Inc. Biomarkers and patient selection strategies
US20200397796A1 (en) 2018-02-26 2020-12-24 Sierra Oncology, Inc. Methods of treatment of cancer comprising chk1 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171470A1 (en) * 2012-05-15 2013-11-21 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof

Also Published As

Publication number Publication date
MX2019012176A (es) 2020-02-19
CN110582490A (zh) 2019-12-17
US20210077499A1 (en) 2021-03-18
CN116999564A (zh) 2023-11-07
CA3059576A1 (en) 2018-10-18
JP2020516693A (ja) 2020-06-11
EP3609884A4 (en) 2021-01-06
AU2018250552A1 (en) 2019-11-14
EP3609884A1 (en) 2020-02-19
JP7273791B2 (ja) 2023-05-15
US11596637B2 (en) 2023-03-07
AU2022259818A1 (en) 2022-12-01
KR20200009004A (ko) 2020-01-29
KR102645511B1 (ko) 2024-03-08
WO2018191277A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
AU2018250552B2 (en) Chk1 (SRA737)/PARPi combination methods of inhibiting tumor growth
Wang et al. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy
WO2018191299A1 (en) Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
KR20180118229A (ko) 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
Rominiyi et al. DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies
JP2014513136A (ja) 脳腫瘍の処置用のｃｓｆ−１ｒ阻害剤
AU2019350581B2 (en) Methods of treatment of cancer comprising Cdc7 inhibitors
Aung et al. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma
US20200157638A1 (en) Biomarkers and patient selection strategies
US20190055563A1 (en) Polymerase q as a target in hr-deficient cancers
US20200397796A1 (en) Methods of treatment of cancer comprising chk1 inhibitors
JP2025525935A (ja) 子宮漿液性がんを治療するためのｗｅｅ１化合物
US20220226338A1 (en) Methods of Treating Cancer Using CHK1 Inhibitors
Przystal et al. DDRE-03. INTERNATIONAL PRECLINICAL DRUG DISCOVERY AND BIOMARKER PROGRAM INFORMING AN ADOPTIVE COMBINATORIAL TRIAL FOR DIFFUSE MIDLINE GLIOMAS
HK40031775B (en) Compounds and methods for treating cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CRT PIONEER FUND LP

Free format text: FORMER OWNER(S): SIERRA ONCOLOGY, INC.